Coats Group (LSE:COA), the industrial thread and footwear components maker, has set out specific targets for the savings and extra sales it expects from OrthoLite, the footwear insole Business it acquired in late 2025. The central question is how Coats plans to capture those synergies, how far it has got eight months after the deal, and how the Acquisition sits alongside its Debt reduction goals and a softer outlook for its end markets.
A global thread and materials group
Coats supplies threads, yarns and related components to apparel and footwear manufacturers worldwide, along with performance materials used in other industrial applications. It reports in US dollars and organises its business into Apparel and Footwear divisions. OrthoLite, which makes footwear insoles and comfort components, has been integrated into the Footwear division. David Paja is group chief executive, and Tim Cobbold chairs the board.
The OrthoLite synergy plan
In its half-year report published on 28 July 2026, Coats said the integration of OrthoLite was progressing well eight months after completion. It expects $5 million of cost synergies in 2026, rising to more than $20 million by 2028. On the Revenue side, it is targeting more than $40 million of incremental annual sales by 2030 and said it had launched four new growth platforms, which had seen encouraging customer traction. The company also identified an incremental $15 million of second-half 2026 benefits from its cost programme, including OrthoLite synergies and operational efficiency measures.
OrthoLite is already influencing margins: Coats said it contributed a 70 basis point Margin benefit in the Footwear division during the first half of the year.
More recently, on 28 September 2026, Coats announced that non-executive director Srinivas Phatak will step down at the end of 2026, that Wu Gang will join the audit and risk committee from 1 January 2027, and that Mr Paja has become chair of the sustainability committee. Mr Cobbold thanked Mr Phatak for his contribution "during a period of strategic transformation."
Financial performance
Revenue in the first half was $837 million, up 1% on an organic, constant-currency basis. Adjusted EBIT was $166 million, a margin of 19.8%, unchanged from a year earlier. Apparel revenue was $486 million, with EBIT of $92 million at an 18.9% margin, helped by China domestic and automotive thread markets. Footwear revenue was $351 million, flat organically excluding OrthoLite, with EBIT of $74 million at a 21.1% margin.
Adjusted Earnings Per Share fell to 4.4 cents from 4.7 cents, and free Cash Flow declined to $30 million from $38 million. The Interim Dividend rose 5% to 1.05 cents per share. Net debt stood at $842 million, equivalent to Leverage of 2.3 times, and the company is targeting 2.0 times by the year end. Mr Paja said Coats remained "very confident in delivering FY results aligned with market expectations."
Risks and points to watch
Coats assumes a modest market decline in the second half despite low customer inventory levels, so Demand in apparel and footwear remains a key variable. Synergy targets stretch to 2028 and 2030, and revenue synergies are typically harder to secure than cost savings. Leverage remains above the company's year-end target, and lower free cash flow and earnings per share in the first half underline the cost of the acquisition. Progress on deleveraging will be a measure of whether OrthoLite is paying its way.
Conclusion
Coats plans to capture OrthoLite synergies through cost savings that build from $5 million this year to over $20 million by 2028, and through new growth platforms aimed at more than $40 million of added sales by 2030. Early signs include a margin benefit in Footwear, but the company's results suggest the full financial payoff, and the reduction in leverage, still lie ahead.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...